News

The VISIBLE study’s findings indicate that specific strategies may yield more diverse populations in clinical trials for patients with psoriasis and other conditions.

A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.

Frissora reviews findings from a cost-effectiveness analysis comparing the Vibrant System to linaclotide for CIC management.

Submission of the Biologics License Application seeks approval of lerodalcibep to lower LDL-C in patients with or at risk for ASCVD and primary hyperlipidemia.

These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.

Study findings suggest the potential utility of ΔADC for assisting the clinical, pathological, and prognostic risk stratification of patients with IgAN.

Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.

In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.

Celltrion’s CT-P43/ustekinumab-stba has been approved under the name Steqeyma and is expected to launch in February 2025.

Resistance is expected to worsen significantly, but can a combination of both ground-level clinician stewardship actions as well as systemic reforms such as the Pasteur Act at least slow down the train?

The sBLA seeks to expand golimumab’s approval for UC to include pediatric patients ≥ 2 years of age and is supported by data from the PURSUIT program.

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.

A hematologist discusses the role of internal and family medicine practitioners in improving the diagnosis and management of iron deficiency.

Steven Fein, MD, discusses news and updates in sickle cell disease following ASH 2024.

In this video, a hematologist discusses trials and areas of advancement he is excited about in the current landscape.

In part 2 of our 5-part series, Steven Fein, MD, discusses updates in iron deficiency management from 2024.

In this video, Steven Fein, MD, discusses updates and topics of note from the American Society of Hematology annual meeting.

Nathan D. Wong, MPH, PhD discusses the evolution of Lp(a) in risk assessment, given its role as a genetic risk factor for cardiovascular complications.

These findings highlight the safety and effectiveness of ESO-101 among adult patients with active eosinophilic esophagitis (EoE).

A study shows young adults with negative emotionality, particularly alienation, who experienced childhood adversities often experience more stressful life events in adulthood.

Clark reviews open-label extension data from the phase 2b SEQUOIA study of fazirsiran for AATD liver disease.

The Boxed Warning is based on the FDA’s review of a postmarketing case of serious liver injury with fezolinetant reported to the FAERS database.

This interview featured a discussion with Browning regarding his team’s findings prior to the FDA approval of tapinarof cream 1% for atopic dermatitis.

Laurence Sperling, MD described the evolving role of cardiologists in obesity care, particularly with the increasing adoption of therapies such as GLP-1 agonists.

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.